BioSpace News Archive

In a video interview on “Hot Topics in Emergency Medicine” posted by Medscape, a group of emergency medicine experts and respiratory physiology thought leaders discussed a new non-invasive measurement; Oxygen Deficit, obtained from the MediPines AGM100, which demonstrated 99% clinical accuracy for supplemental oxygen therapy decisions.

Cytek Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), today announced the company will be participating in the upcoming 20th Annual Morgan Stanley Global Healthcare Conference in New York, NY.

RVL Pharmaceuticals plc (Nasdaq: RVLP) (“RVL” or the “Company”), a specialty pharmaceutical company, announced today that Brian Markison, Chief Executive Officer, will present at the H.C. Wainwright 24th Annual Global Investment Conference.

DW Healthcare Partners (“DWHP”) a healthcare-focused private equity firm, announced the closing of its sale of Med-Pharmex Holdings, Inc (“Med-Pharmex”, or the “Company”) to Dechra Pharmaceuticals PLC (“Dechra”). Med-Pharmex is a leading, fully-integrated veterinary pharmaceutical manufacturer focused on developing, manufacturing, and commercializing animal health drugs.

Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a clinical-stage precision oncology company, today announced that its chief executive officer, Nima Farzan, will participate in a fireside chat at the Wells Fargo Securities Healthcare Conference at the Encore Boston Harbor in Everett, MA on Friday, September 9 at 9:10 AM ET.

Seer, Inc., a life sciences company commercializing a disruptive new platform for proteomics, announced that the company will be participating in the upcoming Morgan Stanley Global Healthcare Conference in New York City, New York.

San Jose BioCube, a leading life-sciences incubator, announced the opening of “BioCube North” at 2680 Zanker Road in North San Jose, California.

Alpha Tau Medical Ltd., the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, announced the Company will participate in person at three upcoming investor conferences in September 2022.

Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay”, “the Company”), a medical diagnostics company focused on developing cost-effective, rapid, near-patient tests for triage and monitoring of disease progression, today announced that Neil Dey, Chief Executive Officer, and Kenneth Fisher, Chief Financial Officer, will present at the H.C. Wainwright 24th Annual Global Investment Conference.